Press Releases

Antios Therapeutics Announces Agreement With IRBM, INGM And OSR To Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) being developed for the treatment of HBV.
IRBM To Collaborate With MSD To Develop Peptides Against Coronavirus

IRBM to collaborate with MSD to develop peptides against coronavirus

Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)
Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2.
DNA IRBM

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics

19th November 2018, Pomezia, Italy – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).

Back To Top